01—Abstract
Summary
Summary of the 10-K filed February 23, 2023. Cited figures are marked; the original filing is the authoritative source.
Pfizer Inc. reported robust financial performance in 2022, with total revenues reaching $100.3 billiona, a significant 23% increase from 2021.
This growth was primarily driven by strong sales from Paxlovid and the Comirnaty vaccine, which together accounted for 57%b of total revenues. Excluding these COVID-19 related products, operational revenue growth was a more modest 2%, supported by key products like the Prevnar family, Eliquis, and Vyndaqel family, as well as contributions from recent acquisitions. The company's strategic focus remains on advancing its pipeline and capitalizing on growth opportunities through both internal R&D and business development.
In 2022, Pfizer completed several strategic acquisitions, including Arena, GBT, and Biohaven, aimed at strengthening its portfolio in immuno-inflammatory diseases and rare diseases. Looking ahead, Pfizer forecasts a significant revenue decline in 2023, primarily due to an expected reduction in COVID-19 product sales, projecting total revenues between $67 billionc and $71 billion. The company continues to manage its cost base, optimize R&D operations, and return capital to shareholders through dividends and share repurchases.
02—Key points
Key Highlights
- Total revenues increased 23% to $100.3 billion in 2022, driven by Paxlovid and Comirnaty.
- Excluding COVID-19 products, operational revenue grew 2%, supported by key products and acquisitions.
- Strategic acquisitions in 2022 included Arena, GBT, and Biohaven to enhance the product pipeline.
- The company forecasts a significant revenue decrease in 2023 to $67-$71 billion, largely due to lower COVID-19 product sales.
- Pfizer continues to invest in R&D and has a strong pipeline of products in various stages of development.
- The company maintained effective internal controls over financial reporting, as audited by independent registered public accounting firm KPMG LLP.
- Pfizer is committed to returning capital to shareholders through dividends and share repurchases, with a remaining share-purchase authorization of approximately $3.3 billion at year-end 2022.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2022filed February 23, 2023Financial Statements
FY2022 against FY2021
| Line item | FY2022FY2021 | Change |
|---|---|---|
| Revenue | $101.17B$81.29B | +24.5% |
| Cost of Revenue | $34.34B$30.82B | +11.4% |
| Gross Profit | $66.83B$50.47B | +32.4% |
| SG&A Expenses | $13.68B$12.70B | +7.7% |
| Interest Expense | $1.24B$1.29B | −4.1% |
| Net Income | $31.37B$21.98B | +42.7% |
| EPS (Basic) | $5.59$3.92 | +42.6% |
| EPS (Diluted) | $5.47$3.85 | +42.1% |
| Shares Outstanding (Basic) | 5.61B5.60B | +0.1% |
| Shares Outstanding (Diluted) | 5.73B5.71B | +0.4% |
05—Questions
Frequently Asked Questions
What were Pfizer's primary revenue drivers in 2022?
Pfizer's primary revenue drivers in 2022 were Paxlovid and Comirnaty, which accounted for 57% of total revenues. Excluding these COVID-19 products, growth was supported by products such as the Prevnar family, Eliquis, and the Vyndaqel family, as well as revenue from recently acquired products.
What is Pfizer's outlook for revenue in 2023?
Pfizer forecasts a significant revenue decline in 2023, projecting total revenues between $67 billion and $71 billion. This is primarily due to an expected reduction in sales of its COVID-19 products, Paxlovid and Comirnaty.
What were Pfizer's key business development activities in 2022?
In 2022, Pfizer completed several strategic acquisitions to strengthen its pipeline and capabilities. Key acquisitions included Arena (focused on immuno-inflammatory diseases), GBT (focused on sickle cell disease), and Biohaven (maker of Nurtec ODT/Vydura for migraine).
How is Pfizer managing its cost structure and operations?
Pfizer is actively managing its cost structure through various initiatives, including optimizing its end-to-end R&D operations, realigning functions, and continuing its 'Transforming to a More Focused Company' program. These efforts aim to reduce costs, improve efficiency, and prioritize its R&D portfolio.
06—Continue